155 related articles for article (PubMed ID: 37921752)
21. Pharmacokinetics, Dialysability, and Safety of Gadopiclenol, a New Gadolinium-Based Contrast Agent, in Patients With Impaired Renal Function.
Bradu A; Penescu M; Pitrou C; Hao J; Bourrinet P
Invest Radiol; 2021 Aug; 56(8):486-493. PubMed ID: 34197356
[TBL] [Abstract][Full Text] [Related]
22. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
23. Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.
Funck-Brentano C; Felices M; Le Fur N; Dubourdieu C; Desché P; Vanhoutte F; Voiriot P
Br J Clin Pharmacol; 2020 Nov; 86(11):2174-2181. PubMed ID: 32302009
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Contrast Enhancement Performance of Gadopiclenol for Magnetic Resonance Angiography in Healthy Rabbits and Pigs.
Hugon G; Adriaensen H; Wintrebert M; Arnould L; Serfaty JM; Robert P
Invest Radiol; 2024 May; ():. PubMed ID: 38709660
[TBL] [Abstract][Full Text] [Related]
25. Summary of preclinical safety evaluation of gadoteridol injection.
Soltys RA
Invest Radiol; 1992 Aug; 27 Suppl 1():S7-11. PubMed ID: 1506157
[TBL] [Abstract][Full Text] [Related]
26. Nonclinical safety profile of tolvaptan.
Oi A; Morishita K; Awogi T; Ozaki A; Umezato M; Fujita S; Hosoki E; Morimoto H; Ishiharada N; Ishiyama H; Uesugi T; Miyatake M; Senba T; Shiragiku T; Nakagiri N; Ito N
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S91-9. PubMed ID: 22120097
[TBL] [Abstract][Full Text] [Related]
27. Review of the Efficacy and Safety of Gadopiclenol: A Newly Emerging Gadolinium-Based Contrast Agent.
Alsogati E; Ghandourah H; Bakhsh A
Cureus; 2023 Aug; 15(8):e43055. PubMed ID: 37680433
[TBL] [Abstract][Full Text] [Related]
28. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
29. Etomidate, a potent non-barbiturate hypnotic. Intravenous etomidate in mice, rats, guinea-pigs, rabbits and dogs.
Janssen PA; Niemegeers CJ; Marsboom RP
Arch Int Pharmacodyn Ther; 1975 Mar; 214(1):92 -132. PubMed ID: 1156027
[TBL] [Abstract][Full Text] [Related]
30. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.
von Keutz E; Schlüter G
Am J Cardiol; 1998 Aug; 82(4B):11J-17J. PubMed ID: 9737641
[TBL] [Abstract][Full Text] [Related]
31. Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging.
Wible JH; Troup CM; Hynes MR; Galen KP; MacDonald JR; Barco SJ; Wojdyla JK; Periasamy MP; Adams MD
Invest Radiol; 2001 Jul; 36(7):401-12. PubMed ID: 11496095
[TBL] [Abstract][Full Text] [Related]
32. Final report on the safety assessment of Trichloroethane.
Int J Toxicol; 2008; 27 Suppl 4():107-38. PubMed ID: 19101834
[TBL] [Abstract][Full Text] [Related]
33. Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance), a new magnetic resonance imaging contrast medium.
Morisetti A; Bussi S; Tirone P; de Haën C
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S207-17. PubMed ID: 10608416
[TBL] [Abstract][Full Text] [Related]
34. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class.
Skov MJ; Beck JC; de Kater AW; Shopp GM
Int J Toxicol; 2007; 26(5):411-21. PubMed ID: 17963128
[TBL] [Abstract][Full Text] [Related]
35. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
[TBL] [Abstract][Full Text] [Related]
36. Toxicological safety assessment of iomeprol, a new X-ray contrast agent.
Morisetti A; Tirone P; Luzzani F; de Haën C
Eur J Radiol; 1994 May; 18 Suppl 1():S21-31. PubMed ID: 8020516
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
Friehe H; Ney P
Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
[TBL] [Abstract][Full Text] [Related]
38. Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses: Current Status of Preclinical and Clinical Studies.
Parillo M; Mallio CA; Van der Molen AJ; Rovira À; Ramalho J; Ramalho M; Gianolio E; Karst U; Radbruch A; Stroomberg G; Clement O; Dekkers IA; Nederveen AJ; Quattrocchi CC;
Invest Radiol; 2023 Aug; 58(8):530-538. PubMed ID: 37185158
[TBL] [Abstract][Full Text] [Related]
39. The reproductive and developmental toxicity of the antifungal drug Nyotran (liposomal nystatin) in rats and rabbits.
Larson JL; Wallace TL; Tyl RW; Marr MC; Myers CB; Cossum PA
Toxicol Sci; 2000 Feb; 53(2):421-9. PubMed ID: 10696790
[TBL] [Abstract][Full Text] [Related]
40. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
